Bilcare is one such company, which provides integrated solutions to pharma companies globally.
Bilcare provides packaging products and clinical research services to pharma companies in India and abroad. It has a global footprint with operations in the US, UK, Germany, Singapore and Brazil. The company has two major business divisions — pharma packaging innovation (PPI), which contributes 83% to its total revenues, and global clinical services (GCS), which accounts for the balance part of its revenue.
Under the PPI division, Bilcare quantifies the sensitivity of drugs and accordingly devises their packaging solutions. The GCS division is a faster growing high-margin business, which provides services like formulation of clinical trials, toxicology studies, batch manufacturing and randomisation.
With four cross-border acquisitions in the past four years, the company has been able to garner a significant chunk of its business from outside India. It is now eyeing significant volumes from the packaging contracts it entered into with Walmart for the latter’s private drug labels. These contracts are serviced through International Labs, a US company in which Bilcare holds 50% stake.
It aims to aggressively scale up its clinical services business and increase the service component in its traditional packaging business.
The company is also in the process of commercially launching its anti-counterfeit packaging solutions based on nano technology by February next year. This technology is aimed at addressing the long-felt need of the pharma industry with regard to fool-proof anti-counterfeiting measures. Considering the growth potential in its new businesses, the company expects to face capacity shortage within the next three years.